In a 34-year-old male with erectile dysfunction who experienced ocular symptoms after sildenafil (Viagra), what is the appropriate workup and treatment?

Switch to an Alternative PDE5 Inhibitor with Lower Ocular Side Effect Profile

For this 34-year-old man who experienced ocular symptoms with sildenafil, switch to tadalafil or avanafil as first-line alternatives, as these agents have different pharmacokinetic profiles and lower rates of visual disturbances. 1

Workup

Essential Laboratory Tests

• Morning total testosterone (if not checked in last 12 months)
• Glucose and lipid profile 1
• Bioavailable or free testosterone if total testosterone is borderline or symptoms suggest hypogonadism (decreased libido, fatigue) 1

When to Pursue Specialized Testing

At age 34, specialized diagnostic tests are not routinely indicated unless specific circumstances exist 1:

• Primary ED (lifelong, not acquired)
• History of pelvic/perineal trauma
• Complex psychiatric or psychosexual disorders
• Patient/partner request

Do not pursue extensive vascular or hormonal workup in routine cases - the evidence for routine hormonal testing remains inconclusive even when abnormalities are found 2.

Treatment Algorithm

First-Line: Alternative PDE5 Inhibitor

Switch to tadalafil (10-20 mg) or avanafil rather than vardenafil, as:

• Sildenafil and vardenafil show dose-related increases in adverse effects including visual disturbances 2
• Tadalafil does not show the same dose-response relationship for side effects 2
• The incidence of visual disturbances (blue-green color discrimination problems, photophobia, blurred vision) is a known class effect but varies by agent 3

Critical Safety Counseling

Before prescribing any PDE5 inhibitor, verify:

• No nitrate use (absolute contraindication) 2, 3
• No alpha-blocker use without dose adjustment 3
• No protease inhibitors (may require 25 mg maximum dose in 48 hours) 3

Warn about serious ocular complications:

• Stop medication immediately if sudden vision loss occurs in one or both eyes 3
• While rare, non-arteritic anterior ischemic optic neuropathy (NAION), retinal vascular occlusions, and maculopathy have been reported, even in young healthy men 4, 5, 6, 7
• Risk may be higher in those with prior NAION in one eye 3

Second-Line Options if PDE5 Inhibitors Fail or Are Not Tolerated

1. Intracavernous injection therapy (alprostadil, papaverine, phentolamine combinations) - mean IIEF-EF improvement of 3.21 points 1

2. Vacuum erection devices - 90% initial effectiveness 1

3. Combination therapy: PDE5 inhibitor + testosterone (if hypogonadal) may help nonresponders 1

4. Psychosocial intervention: Sexual skills training or cognitive behavioral therapy, especially if psychogenic component exists 1

Testosterone Therapy Considerations

Only add testosterone if:

• Morning total testosterone is low
• Patient has symptoms beyond ED (decreased libido, fatigue)
• Physical findings suggest hypogonadism (testicular/muscle atrophy) 2

Evidence for testosterone alone in ED is weak - even in hypogonadal men, studies show inconsistent effects 2. Testosterone may augment PDE5 inhibitor response in hypogonadal nonresponders 1.

Common Pitfalls to Avoid

• Don't dismiss ocular symptoms - while most are mild (color vision changes, photophobia), rare cases of permanent vision loss from NAION or retinal vascular occlusion occur even in young, healthy patients 4, 5, 6, 7
• Don't assume all PDE5 inhibitors are equivalent - patient preference, adverse effect profile, and pharmacokinetics differ meaningfully 1, 2
• Don't order extensive hormonal workup routinely - individualize based on clinical presentation, not protocol 2
• Don't use multiple PDE5 inhibitors simultaneously or combine with other erectogenic treatments without specialist guidance 3